Completed
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
NCT03157830
- Conditions
- Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
- Locations
-
- RWJBarnabas Health Livingston, New Jersey, United States
- Providence MS Center Portland, Oregon, United States
- Kadlec Neuroscience Center Richland, Washington, United States
- Multiple Sclerosis Center, Swedish Neuroscience Institute Seattle, Washington, United States